Regulus Therapeutics (RGLS) Given News Sentiment Score of 0.21

News stories about Regulus Therapeutics (NASDAQ:RGLS) have been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.0030532909391 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Regulus Therapeutics (RGLS) opened at $1.20 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $1.95.

A number of research firms have issued reports on RGLS. Zacks Investment Research downgraded Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Chardan Capital reaffirmed a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Leerink Swann began coverage on Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a research note on Monday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. Regulus Therapeutics currently has a consensus rating of “Hold” and an average price target of $2.50.

TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/18/regulus-therapeutics-rgls-receiving-somewhat-favorable-press-coverage-report-finds.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply